Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 50 for Multiple myeloma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study to Evaluate the Safety and Effectiveness of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study to Evaluate the Safety and Effectiveness of Metformin in Combination with Nelfinavair with or without Bortezomib in Relapsed and/or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

    Rochester, MN

  8. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration

    Eau Claire, WI, Rochester, MN

  9. Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Rochester, MN

  10. Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

    Jacksonville, FL, Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer